Severe aplastic anemia is a condition where the bone marrow does not create enough blood cells, leading to risks of infection and bleeding. This study aims to help patients with this condition by using a haploidentical bone marrow transplant, which is a transplant from a partially matched family member. The treatment includes medications like Fludarabine, Cyclophosphamide, and Tacrolimus to prepare the body and prevent complications. Cyclophosphamide is given after the transplant to help the body accept the new bone marrow.

Key points to consider:

• The study involves multiple hospital visits over 180 days for treatment and medication.
• Eligibility requires having a specific type of family donor and being under certain age limits.
• Risks include potential graft failure (less than 30% chance) and side effects from medications.

Patients with poor heart, lung, liver, or kidney function are not eligible. The study will include 20 patients to confirm the success rate of the transplant method.